For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? The ...

Core Insights - Amgen's upcoming quarterly earnings report is projected to show earnings of $4.15 per share, a 4.8% increase year-over-year, with revenues expected to reach $7.96 billion, reflecting a 6.8% growth compared to the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised downward by 1.6%, indicating a reassessment by analysts [1][2] Revenue and Product Sales Estimates - Analysts forecast 'Product Sales- BLINCYTO- Total' to be $332.73 million, marking a 36.4% increase from the prior year [4] - 'Product Sales- Repatha- Total' is expected to reach $616.47 million, indicating a 19.2% year-over-year growth [4] - 'Product Sales- KYPROLIS- Total' is estimated at $381.49 million, reflecting a 1.5% increase from the previous year [4] - 'Product Sales- Vectibix- Total' is projected at $248.09 million, a slight increase of 0.4% year-over-year [5] - 'Product Sales- Neulasta- U.S.' is expected to decline to $67.86 million, a decrease of 22% from the prior year [5] - 'Product Sales- Neulasta- ROW' is estimated at $26.10 million, indicating a 15.8% decline year-over-year [5] - 'Product Sales- EPOGEN- U.S.' is projected to be $30.98 million, reflecting a 24.4% decrease [6] - 'Product Sales- Repatha- ROW' is expected to reach $295.07 million, a 20.9% increase from the previous year [6] - 'Product Sales- Repatha- U.S.' is projected at $331.22 million, indicating a 21.3% increase year-over-year [6] - 'Product Sales- KYPROLIS- ROW' is estimated at $147.40 million, reflecting a 3.8% increase [7] - 'Product Sales- BLINCYTO- U.S.' is expected to be $207.37 million, a 35.5% increase year-over-year [7] - 'Product Sales- BLINCYTO- ROW' is projected at $117.02 million, indicating a 28.6% increase from the prior year [7] Stock Performance - Over the past month, Amgen's shares have decreased by 8.5%, compared to a 4.3% decline in the Zacks S&P 500 composite [7]